This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
3 Airlines Stocks to Gain as the Economy Looks to Fully Reopen
by Zacks Equity Research
Rollout of the vaccine along with an expected fiscal stimulus is sure to boost the airlines industry, making it prudent to watch out for names like Mesa Air Group (MESA) and Spirit Airlines (SAVE).
Small-Caps at Record Highs Ahead of Christmas
by Mark Vickery
The small-cap Russell 2000 index has hit another closing record high today -- the 13th time this has occurred this year.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $37.44, moving +1.91% from the previous trading session.
Top Stock Reports for Apple, JPMorgan & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan Chase (JPM), and Union Pacific (UNP).
5 Best-Performing Leveraged ETFs of Fourth Quarter
by Sweta Killa
We highlight some leveraged ETFs that gained more than 85% over the past three months.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
by Zacks Equity Research
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
4 MedTech Stocks Up More Than 100% in 2020 With Room to Run
by Urmimala Biswas
We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
How Effective Will Vaccines be Against New Coronavirus Strain?
by Indrajit Bandyopadhyay
Pfizer (PFE) and Moderna (MRNA), the companies whose coronavirus vaccines have been approved for emergency use, are evaluating their vaccines against the fast-spreading new strain of coronavirus found in the United Kingdom.
5 High Beta & Momentum ETFs to Tap the Santa Rally
by Sweta Killa
These ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
3 Large Drugmakers Set to Rule the Sector in 2021
by Kinjel Shah
Large Cap Pharmaceuticals industry players maintain a cautious outlook after mixed Q3 show. COVID-19 vaccine development efforts play a crucial role in driving the industry. PFE, MRK, NVS may prove to be good additions to your portfolio.
4 Restaurant Stocks to Play a Likely Turnaround in 2021
by Mrithunjoy Kaushik
Although the restaurant industry is grappling with the coronavirus outbreak, restaurant stocks like JACK, RUTH, FAT and STKS have impressive 2021 earnings growth projections.
Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.
4 Airline Stocks Took Off on Vaccine Hopes: Can They Keep Flying in 2021?
by Maharathi Basu
IATA forecasts airline loss to narrow in 2021 from $118.5 billion predicted in 2020. This improved scenario should aid stocks like United Airlines (UAL), American Airlines (AAL), Spirit Airlines (SAVE) and Mesa Air (MESA).
More New Highs for Stocks With Fiscal Stimulus Looking Imminent
by David Borun
Even with rising Covid-19 cases, a deal in Washington and the vaccine rollout keep investors in a buying mood.
5 Small-Cap ETFs Set to Explode on COVID-19 Vaccines
by Sweta Killa
As the economy seems on track for strong growth, a small-cap rally is expected to strengthen in the New Year.
Christmas Week Begins With Pre-market Sell-off
by Zacks Equity Research
Christmas Week Begins With Pre-market Sell-off
Pre-Markets Down to Start Christmas Week
by Mark Vickery
Though already off the lows we saw a couple hours before today's opening bell, the Dow is down 400 points, the S&P 500 -55 and the Nasdaq -140.
Top 5 S&P 500 Stocks That Helped the Index Gain in 2020
by Aniruddha Ganguly
Here we pick five S&P 500 stocks -- NVDA, ETSY, AAPL, MSFT & AMZN -- that have helped the index deliver solid returns this year.
Moderna (MRNA) Gets FDA Emergency Use Nod for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) gets emergency use authorization for coronavirus vaccine, mRNA-1273, for use in adults in the United States.
4 Restaurant Stocks to Watch as Vaccine Rollout Begins
by Zacks Equity Research
Vaccine rollout should allow dine-in to resume in restaurants with online delivery expected to sustain, making it prudent to keep an eye on names like Brinker International (EAT) and McDonald's (MCD)
Vaccines to Fuel Santa Claus Rally: 5 Stock Picks
by Sweta Killa
With only eight trading days left this year, markets are bracing for the so-called Santa Claus rally.
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use to Moderna's (MRNA) coronavirus vaccine candidate.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.